Development of prolonged release hydrogel oral dosage form of Physostigmine

dc.contributor.committeeMemberFeldman, Stuart
dc.contributor.committeeMemberGupta, V. Das
dc.contributor.committeeMemberWhite, Catherine A.
dc.contributor.committeeMemberDriever, Carl W.
dc.contributor.committeeMemberMack, Eric J.
dc.creatorKumi, Kofi Amoa
dc.date.accessioned2024-01-10T20:42:13Z
dc.date.available2024-01-10T20:42:13Z
dc.date.issued1988
dc.description.abstractAlzheimer's disease (AD) is an insidious, degenerative, debilitating disease of the brain. AD is characterized by relentless, irreversible deterioration of intellect, cognition, emotions and behavior. Biochemically, deficits in a number of neurotransmitters and neuropeptides have been observed. The most consistent biochemical deficit observed is a decrease in acetylcholine levels. Current therapy has been directed to rectify this deficit found in the cholinergic system. One category of drugs tried is the cholinesterase inhibitors which prevent the breakdown of acetylcholine. Physostigmine (PSM) is an anticholinesterase that has shown encouraging results. The major problems associated with PSM are the need for frequent dosing due to PSM short half life and the high incidence of side effects due to PSM narrow therapeutic range. An oral prolonged release dosage form may help to alleviate these problems. Hydrogels are biocompatible polymeric materials which swell in water and other solvents, absorbing the fluid within the polymer network without dissolving themself. Hydrogels, copoly-merized from a neutral monomer, 2- hydroxyethyImethacrylate (HEMA), a monomer capable of becoming negatively charged, methacrylic acid (MAA), or N,N dimethylacrylamide (NND), a monomer capable of becoming positively charged, by free radical polymerization were investigated as prolonged release devices for PSM. [...]
dc.description.departmentPharmacy, College of
dc.format.digitalOriginreformatted digital
dc.format.mimetypeapplication/pdf
dc.identifier.other19418002
dc.identifier.urihttps://hdl.handle.net/10657/15866
dc.language.isoen
dc.rightsThis item is protected by copyright but is made available here under a claim of fair use (17 U.S.C. Section 107) for non-profit research and educational purposes. Users of this work assume the responsibility for determining copyright status prior to reusing, publishing, or reproducing this item for purposes other than what is allowed by fair use or other copyright exemptions. Any reuse of this item in excess of fair use or other copyright exemptions requires express permission of the copyright holder.
dc.subjectCholinesterase inhibitors
dc.subjectColloids in medicine
dc.titleDevelopment of prolonged release hydrogel oral dosage form of Physostigmine
dc.type.dcmiText
dc.type.genreThesis
thesis.degree.collegeCollege of Pharmacy
thesis.degree.departmentPharmacy, College of
thesis.degree.disciplinePharmacy
thesis.degree.grantorUniversity of Houston
thesis.degree.levelMasters
thesis.degree.nameMaster of Science

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Kumi_1988_19418002.pdf
Size:
2.64 MB
Format:
Adobe Portable Document Format